Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alvin Wee

Urology Indianapolis, IN Medical Doctor

NPI 1558539874 CMS profile 578147

8333 Naab Rd Ste 300, Indianapolis, IN 46260

Open in the dashboard

General payments

$46,104

111 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alvin Wee of Indianapolis, IN is reported in the CMS Open Payments database as having received $46,104 across 111 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,758 28
2024 General $4,235 15
2023 General $4,772 16
2022 General $20,796 28
2021 General $6,714 12
2020 General $2,588 8
2019 General $241 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alvin Wee
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Alvin Wee were reported at $6,758. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Alvin Wee Urology median Middle half National median
2019 $241 $480 $147–$1,201 $163
2020 $2,588 $246 $87–$645 $114
2021 $6,714 $358 $111–$1,000 $132
2022 $20,796 $476 $143–$1,263 $149
2023 $4,772 $560 $168–$1,461 $160
2024 $4,235 $563 $170–$1,464 $164
2025 $6,758 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Veloxis Pharmaceuticals, Inc. $33,040 39 payments
  2. Globus Medical, Inc. $3,648 9 payments
  3. TransMedics, Inc. $3,184 2 payments
  4. Medtronic, Inc. $1,765 19 payments
  5. VB Spine LLC $1,623 7 payments
  6. Dilon Technologies, Inc. $425 3 payments
  7. XVIVO Perfusion Inc. $389 3 payments
  8. Intuitive Surgical, Inc. $273 4 payments
  9. AstraZeneca Pharmaceuticals LP $239 2 payments
  10. Ethicon US, LLC $223 6 payments
  11. Other $1,295 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $23,500 11 payments
  2. Travel and Lodging $12,901 25 payments
  3. Food and Beverage $5,703 73 payments
  4. Honoraria $4,000 2 payments
Products named General payments · program years 2019–2025
  1. Envarsus Immunosuppresant $26,648 30 payments
  2. ENVARSUS Transplantation $4,279 7 payments
  3. ORGAN CARE SYSTEM $3,184 2 payments
  4. ALIF $3,126 5 payments
  5. Envarsus Immunosuppressant $2,114 2 payments
  6. Spine Guidance Software $1,056 1 payment
  7. XLIF $509 3 payments
  8. Signia $508 4 payments
  9. MONTEREY AL $463 2 payments
  10. HEMOBLAST BELLOWS $425 3 payments
  11. Other $4,213 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

57

Median for Urology: 1,053

Drug cost

$347

Median for Urology: $101,464

Branded share of claims

36.8%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 21 $184
Amlodipine Besylate Generic 12 $84
Atorvastatin Calcium Generic 12 $55
Finasteride Generic 12 $24

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$105,181

Medicare's payments for the services billed

Medicare patients

124

Average age 64

Services billed

327

46 women, 78 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Diabetes 50%
Ischemic heart disease 37%
Heart failure 34%
Arthritis 34%
Atrial fibrillation 31%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

111 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record